Skip to main content
SpringerLink
Log in

Göteborg-2-Studie – PSA(prostataspezifisches Antigen)-basiertes Prostatakarzinomscreening mit frühzeitigem Start vor dem 55. Lebensjahr

Göteborg 2 study—early PSA-based prostate cancer screening prior to the age of 55 years

  • Journal Club
  • Published:
Die Urologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027–2035

    Article  PubMed  PubMed Central  Google Scholar 

  2. de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ (2023) A detailed evaluation of the effect of prostate-specific antigen—based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the rotterdam section of the European Randomised study of screening for prostate cancer. Eur Urol 5:S0302–2838(23)02669-6. https://doi.org/10.1016/j.eururo.2023.03.016. Online ahead of print.PMID: 37029074

  3. Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A et al (2016) Screening for prostate cancer starting at Age 50–54 years. A population-based cohort study. Eur Urol 71(1):46–52. https://doi.org/10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13 (http://linkinghub.elsevier.com/retrieve/pii/S0302283816003766)

  4. Ilic D, Neuberger M, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004720.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  5. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J (2014) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):1–7 (http://linkinghub.elsevier.com/retrieve/pii/S0302283814012615)

    Google Scholar 

  6. Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M et al (2021) MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med 385(10):908–920. https://doi.org/10.1056/NEJMoa2100852. Epub 2021 Jul 9. (http://www.ncbi.nlm.nih.gov/pubmed/34237810)

  7. Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L et al (2022) Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med 387(23):2126–2137 (http://www.ncbi.nlm.nih.gov/pubmed/36477032)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Krilaviciute A, Albers P, Lakes J, Radtke JP, Herkommer K, Gschwend J et al (2023) Adherence to a risk-adapted screening strategy for prostate cancer: first results of the PROBASE trial. Int J Cancer 152(5):854–864

    Article  CAS  PubMed  Google Scholar 

  9. Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M et al (2021) Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol 22(9):1240–1249

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    Benedikt Wolframm, Anne Hübner, Isabelle Bushoff, Jale Lakes, Rouvier Al-Monajjed, Peter Albers &  Jan Philipp Radtke

  2. Klinik für Urologie, Marienhospital Herne, Klinikum der Ruhr-Universität Bochum, Herne, Deutschland

    Analena Elisa Handke

  3. Abteilung für Personalisierte Früherkennung des Prostatakarzinoms, Deutsches Krebsforschungszentrum (dkfz), Heidelberg, Deutschland

    Peter Albers

  4. Abteilung Radiologie, Deutsches Krebsforschungszentrum (dkfz), Heidelberg, Deutschland

    Jan Philipp Radtke

Authors
  1. Benedikt Wolframm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Analena Elisa Handke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabelle Bushoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jale Lakes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rouvier Al-Monajjed
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan Philipp Radtke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Philipp Radtke.

Ethics declarations

Interessenkonflikt

B. Wolframm, A. Hübner, A.E. Handke, I. Bushoff, J. Lakes, R. Al-Monajjed, P. Albers und J.P. Radtke geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolframm, B., Hübner, A., Handke, A.E. et al. Göteborg-2-Studie – PSA(prostataspezifisches Antigen)-basiertes Prostatakarzinomscreening mit frühzeitigem Start vor dem 55. Lebensjahr. Urologie 62, 727–729 (2023). https://doi.org/10.1007/s00120-023-02112-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-023-02112-6

Search

Navigation